ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment [Back Bay Transaction]
Copenhagen-based ISD Immunotech (ISD), a Novo Seeds Portfolio Company, today announced a strategic research collaboration with Cambridge, MA-based Biogen (Nasdaq: BIIB) to advance ISD’s lead compound in development to treat severe lupus - systemic lupus erythematosus (SLE).
Back Bay Life Science Advisors is proud to serve as strategic and financial advisor to ISD Immunotech in negotiations enabling the agreement.
As part of the collaboration, ISD Immunotech, and Biogen will develop ISD 017, a proprietary and novel peptide therapeutic which is an inhibitor of the STING pathway and will “aim to deliver one of the first new therapies to treat severe SLE in over 50 years,” according to the recent announcement.
Current ISD investor Novo Seeds provided additional funding to accelerate the development of ISD 017. Novo Seeds is the early-stage investment and company creation arm group of Novo Holdings A/S, a private limited liability company wholly owned by the Novo Nordisk Foundation.
Back Bay’s investment banking team has extensive experience in cross-border licensing, partnering, M&A, and furthering global research collaborations between emerging biotechnology and large pharma across all sectors.
Our warmest congratulations to ISD Immunotech, Biogen, and Novo Seeds in their alliance to address unmet needs for people with severe SLE.